167 related articles for article (PubMed ID: 32628088)
1.
Costa EFD; Lima TRP; Lopes-Aguiar L; Nogueira GAS; Visacri MB; Quintanilha JCF; Pincinato EC; Calonga L; Mariano FV; Altemani AMAM; Altemani JMC; Moriel P; Chone CT; Ramos CD; Lima CSP
Tumour Biol; 2020 Jul; 42(7):1010428320938494. PubMed ID: 32628088
[TBL] [Abstract][Full Text] [Related]
2. Genetic variability in cisplatin metabolic pathways and outcome of locally advanced head and neck squamous cell carcinoma patients.
Ferreira AMC; Altemani JMC; Macedo LT; Lourenço GJ; Lima CSP
Sci Rep; 2023 Oct; 13(1):16762. PubMed ID: 37798436
[TBL] [Abstract][Full Text] [Related]
3. GSTP1 c.313A>G, XPD c.934G>A, XPF c.2505T>C and CASP9 c.-1339A>G Polymorphisms and Severity of Vomiting in Head and Neck Cancer Patients treated with Cisplatin Chemoradiation.
Carron J; Lopes-Aguiar L; Costa EFD; Nogueira GAS; Lima TRP; Pincinato EC; Visacri MB; Quintanilha JCF; Moriel P; Lourenço GJ; Lima CSP
Basic Clin Pharmacol Toxicol; 2017 Dec; 121(6):520-525. PubMed ID: 28686330
[TBL] [Abstract][Full Text] [Related]
4. Influence of CASP9 c.-1339A>G and CASP3 c.-1191A>G variants in outcome of patients with head and neck squamous cell carcinoma.
Carvalho BF; Costa EFD; Lopes-Aguiar L; Liutti VT; Leal F; Vasconcelos VCA; Rinck-Junior JA; Lourenço GJ; Lima CSP
J Oral Pathol Med; 2020 Nov; 49(10):1078-1083. PubMed ID: 32816327
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma.
Sun T; Miao X; Zhang X; Tan W; Xiong P; Lin D
J Natl Cancer Inst; 2004 Jul; 96(13):1030-6. PubMed ID: 15240787
[TBL] [Abstract][Full Text] [Related]
6. Site disparities in apoptotic variants as predictors of risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck.
Sun Y; Yu W; Sturgis EM; Peng W; Lei D; Wei Q; Song X; Li G
BMC Cancer; 2016 Feb; 16():70. PubMed ID: 26858129
[TBL] [Abstract][Full Text] [Related]
7. CASP9 c.-1339A>G and CASP3 c.-1191A>G polymorphisms alter susceptibility and clinical aspects of head and neck squamous cell carcinoma.
Costa EFD; Lopes-Aguiar L; Nogueira GS; Lima TRP; Rinck-Junior JA; Lourenço GJ; Lima CSP
Head Neck; 2019 Aug; 41(8):2665-2670. PubMed ID: 30903678
[TBL] [Abstract][Full Text] [Related]
8. GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms in outcomes of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation.
Pincinato EC; Costa EFD; Lopes-Aguiar L; Nogueira GAS; Lima TRP; Visacri MB; Costa APL; Lourenço GJ; Calonga L; Mariano FV; Altemani AMAM; Coutinho-Camillo C; Chone CT; Ramos CD; Altemani JMC; Moriel P; Lima CSP
Sci Rep; 2019 Jun; 9(1):9312. PubMed ID: 31249357
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes.
Li Y; Hao YL; Kang S; Zhou RM; Wang N; Qi BL
Gynecol Oncol; 2013 Mar; 128(3):584-9. PubMed ID: 23234803
[TBL] [Abstract][Full Text] [Related]
10. XPD c.934G>A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation.
Lopes-Aguiar L; Costa EF; Nogueira GA; Lima TR; Visacri MB; Pincinato EC; Calonga L; Mariano FV; de Almeida Milani Altemani AM; Altemani JM; Coutinho-Camillo CM; Ribeiro Alves MA; Moriel P; Ramos CD; Chone CT; Lima CS
Oncotarget; 2017 Mar; 8(10):16190-16201. PubMed ID: 26918827
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma.
Cao Y; Miao XP; Huang MY; Deng L; Lin DX; Zeng YX; Shao JY
Mol Carcinog; 2010 Nov; 49(11):944-50. PubMed ID: 20842669
[TBL] [Abstract][Full Text] [Related]
12. ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy.
Guberina M; Sak A; Pöttgen C; Tinhofer-Keilholz I; Budach V; Balermpas P; Von der Grün J; Rödel CM; Gkika E; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; De-Colle C; Welz S; Linge A; Lohaus F; Baretton G; Gauler T; Baumann M; Krause M; Schuler M; Bankfalvi A; Höing B; Lang S; Stuschke M
Pharmacogenomics J; 2021 Feb; 21(1):37-46. PubMed ID: 32546699
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer.
Park JY; Lee WK; Jung DK; Choi JE; Park TI; Lee EB; Cho S; Park JY; Cha SI; Kim CH; Kam S; Jung TH; Jheon S
Clin Cancer Res; 2009 Mar; 15(5):1794-800. PubMed ID: 19240174
[TBL] [Abstract][Full Text] [Related]
14. FAS and FASLG genetic variants and risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck.
Lei D; Sturgis EM; Wang LE; Liu Z; Zafereo ME; Wei Q; Li G
Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1484-91. PubMed ID: 20501759
[TBL] [Abstract][Full Text] [Related]
15. Association between genetic polymorphisms in DNA mismatch repair-related genes with risk and prognosis of head and neck squamous cell carcinoma.
Nogueira GA; Lourenço GJ; Oliveira CB; Marson FA; Lopes-Aguiar L; Costa EF; Lima TR; Liutti VT; Leal F; Santos VC; Rinck-Junior JA; Lima CS
Int J Cancer; 2015 Aug; 137(4):810-8. PubMed ID: 25598504
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility to oral cancers with CD95 and CD95L promoter SNPs may vary with the site and gender.
Daripally S; Nallapalle SR; Katta S; Prasad VV
Tumour Biol; 2015 Sep; 36(10):7817-30. PubMed ID: 25944167
[TBL] [Abstract][Full Text] [Related]
17. FasL -844T/C and Fas -1377G/A: mutations of pulmonary adenocarcinoma in South China and their clinical significances.
Zhao H; Chen W; Du P; Sun A; Zhuang C; Tong J; Wang L
Tumour Biol; 2015 Jun; 36(6):4319-26. PubMed ID: 25596086
[TBL] [Abstract][Full Text] [Related]
18. Functional polymorphisms in FAS and FASL contribute to risk of squamous cell carcinoma of the larynx and hypopharynx in a Chinese population.
Wang J; Gao J; Li Y; Zhao X; Gao W; Peng L; Yan D; Liu L; Li D; Wei L; Qi J; Zhou C
Gene; 2013 Jul; 524(2):193-6. PubMed ID: 23618817
[TBL] [Abstract][Full Text] [Related]
19. 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck - a multicentre, retrospective analysis.
Helfenstein S; Riesterer O; Meier UR; Papachristofilou A; Kasenda B; Pless M; Rothschild SI
Radiat Oncol; 2019 Feb; 14(1):32. PubMed ID: 30744643
[TBL] [Abstract][Full Text] [Related]
20. Association of genetic variants in apoptosis genes FAS and FASL with radiation-induced late toxicity after prostate cancer radiotherapy.
Thurner EM; Krenn-Pilko S; Langsenlehner U; Renner W; Gerger A; Kapp KS; Langsenlehner T
Strahlenther Onkol; 2014 Mar; 190(3):304-9. PubMed ID: 24424626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
